James F. Trotter – 23 September 2013

Neil Mehta, Jennifer L. Dodge, Aparna Goel, John Paul Roberts, Ryutaro Hirose, Francis Y. Yao – 23 September 2013 – It has been shown that patients with hepatocellular carcinoma (HCC) meeting the United Network for Organ Sharing T2 (Milan) criteria have an advantage in comparison with patients without HCC under the current organ allocation system for liver transplantation (LT). We hypothesized that within the T2 HCC group, there is a subgroup with a low risk of wait‐list dropout that should not receive the same listing priority.

Robert W. Krell, Daniel R. Kaul, Andrew R. Martin, Michael J. Englesbe, Christopher J. Sonnenday, Shijie Cai, Preeti N. Malani – 23 September 2013 – Although sarcopenia (muscle loss) is associated with increased mortality after liver transplantation, its influence on other complications is less well understood. We examined the association between sarcopenia and the risk of severe posttransplant infections among adult liver transplant recipients. By calculating the total psoas area (TPA) on preoperative computed tomography scans, we assessed sarcopenia among 207 liver transplant recipients.

Deirdre A. Kelly – 23 September 2013

Luca Quagliata, Matthias S. Matter, Salvatore Piscuoglio, Leila Arabi, Christian Ruiz, Alfredo Procino, Michal Kovac, Francesca Moretti, Zuzanna Makowska, Tujana Boldanova, Jesper B. Andersen, Monika Hämmerle, Luigi Tornillo, Markus H. Heim, Sven Diederichs, Clemente Cillo, Luigi M. Terracciano – 20 September 2013 – Hepatocellular carcinoma (HCC) is among the leading causes of cancer‐related death. Despite the advances in diagnosis and management of HCC, the biology of this tumor remains poorly understood.

Sheida Moghadamrad, Matteo Montani, Andrea De Gottardi – 20 September 2013

A.S. Knisely – 20 September 2013

Monica A. Konerman, Shruti H. Mehta, Catherine G. Sutcliffe, Trang Vu, Yvonne Higgins, Michael S. Torbenson, Richard D. Moore, David L. Thomas, Mark S. Sulkowski – 20 September 2013 – Human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfection is associated with progressive liver disease. However, the rate of progression is variable and the ability to differentiate patients with stable versus progressive HCV disease is limited. The objective of this study was to assess the incidence of and risk factors for fibrosis progression in a prospective cohort of coinfected patients.

Monica A. Konerman, Shruti H. Mehta, Catherine G. Sutcliffe, Trang Vu, Yvonne Higgins, Michael S. Torbenson, Richard D. Moore, David L. Thomas, Mark S. Sulkowski – 20 September 2013 – Human immunodeficiency virus (HIV)/hepatitis C virus (HCV) coinfection is associated with progressive liver disease. However, the rate of progression is variable and the ability to differentiate patients with stable versus progressive HCV disease is limited. The objective of this study was to assess the incidence of and risk factors for fibrosis progression in a prospective cohort of coinfected patients.

Harald Schrem, Marlene Kurok, Alexander Kaltenborn, Arndt Vogel, Ulla Walter, Lea Zachau, Michael P. Manns, Jürgen Klempnauer, Moritz Kleine – 14 September 2013 – The goal of this study was the characterization of long‐term cancer risks after liver transplantation (LT) with implications for prevention and detection.